Chronic Airways Assessment Test (CAAT)
Chronic Airways Assessment Test: A unified tool for assessing chronic airway diseases
CAAT can now be used for assessing respiratory health status in people with asthma, not just COPD
A simple and standardized health status measure
A standardized, easy to administer, health status measure for use across obstructive lung diseases.
Structure and components of the CAAT
8-items assessing aspects of disease relevant to patients.
Development and validation
The COPD assessment test (CAT) and the Chronic Airways Test (CAAT) were developed by an interdisciplinary group of international experts with support from GSK.
CAT and CAAT activities are monitored by a supervisory council that includes independent experts, one of which is chair of the council.
CAT, COPD Assessment Test, CAAT, Chronic Airways Assessment Test and the CAT logo are trademarks of the GSK group of companies.
Implementation and resources
Scan the QR code for the CAAT User Guide.
Documents for download
Read more details at
Fecha de publicación
September 2025
Categorías asociadas al artículo
Noticias relacionadas
The ROME COPD exacerbation proposal works! Time to move forward
The ROME proposal for COPD exacerbations classification offers a new approach to assess severity and predict outcomes, improving clinical decision-making
COPD Management in Primary Care: Underutilisation of Nursing Consultations
Analysis of COPD management in primary care highlighting the role and underutilisation of nursing consultations and healthcare utilisation patterns in real-world patients.
Addressing the Global Challenges of COPD and Asthma: A Shared Vision From the Global Initiative for Chronic Obstructive Pulmonary Disease (GOLD) and the Global Initiative for Asthma (GINA)
Analysis of the global challenges of COPD and asthma and the shared vision of GOLD and GINA to improve diagnosis, access to inhaled therapies and patient outcomes worldwide.
Joint statement from GOLD/GLI regarding the use of spirometry to define airflow obstruction and diagnose COPD
Joint GOLD/GLI statement on spirometry to define airflow obstruction and confirm COPD diagnosis, aiming to harmonize criteria and improve global practice.
Climate change and respiratory health: implications for respiratory clinicians in primary and specialist care
Review on climate change and respiratory health, focusing on chronic respiratory diseases and implications for primary and specialist care.
cfDNA profiling in COPD
Whole-genome cfDNA profiling identifies molecular clusters and pathways associated with oxidative damage and airflow limitation in COPD patients.
Imagen obtenida de la presentación